Screening for Hypogonadism in Primary Healthcare: How to do this Effectively
received 11. Februar 2017
revised 11. Juni 2017
accepted 23. Juni 2017
24. Januar 2018 (online)
Background Testosterone, the most important androgen produced by the testes, plays an integral role in male health. Testosterone levels are increasingly being checked in primary healthcare as awareness of the risks of male hypogonadism grows.
Aim To investigate what tests are performed to screen for hypogonadism and to exclude secondary hypogonadism.
Design and Setting All participants attended general practices in the UK.
Methods Data search was performed using the EMIS® clinical database (provider of the majority of GP operating systems in Cheshire). The anonymised records of male patients aged 18–98 years who had undergone a check of serum testosterone during a 10-year period were analysed.
Results Overall screening rate was 4.3%. Of 8 788 men with a testosterone result, 1 924 men (21.9%) had a total testosterone level <10 nmol/L. Just 689 of 8 788 men (7.8%) had a sex hormone-binding globulin (SHBG) result, corresponding to 30.5% of those potentially hypogonadal. Estimated free testosterone was negatively associated with BMI (Spearman’s rho -0.2, p<0.001) as was total testosterone in the over 50 s. Of 1 924 potentially hypogonadal men with a serum testosterone <10 nmol/L, 588 of 1 924 (30.6%) had a check of serum prolactin. 46.3% and 41.7% had LH and FSH measured, respectively. Only 19.1% of 1 924 men with a hypogonadal total testosterone level were subsequently put on testosterone replacement. The percentage of men in the relatively socially disadvantaged category was similar for both eugonadal and hypogonadal men with a much higher rate of screening for hypogonadism in more socially advantaged men.
Conclusions Screening in primary healthcare identified a significant minority of men who had potential hypogonadism. Interpretation of a low serum testosterone requires measurement of serum prolactin, LH and FSH in order to rule out secondary hypogonadism. We suggest that this becomes part of routine screening with a balanced screening approach across the socioeconomic spectrum.
- 1 Mooradian AD, Morley JE, Korenman SG. Biological actions of androgens. Endocr Rev 1987; 8: 1-28
- 2 British Society for Sexual Medicine. Guidelines on the management of sexual problems in men: the role of androgens (2010). http://www.bssm.org.uk/downloads/UK_Guidelines_Androgens_Male_2010.pdf Document last accessed: October 17, 2016
- 3 Kapoor D, Clarke S, Channer KS. et al. Erectile dysfunction is associated with low bioactive testosterone levels and visceral adiposity in men with type 2 diabetes. Int J Androl 2007; 30: 500-507
- 4 Harman SM, Metter EJ, Tobin JD. et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging. J Clin Endocrinol Metab 2001; 86: 724-731
- 5 Araujo AB, Esche GR, Kupelian V. et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab 2007; 92: 4241-4247
- 6 Araujo AB, O'Donnell AB, Brambilla DJ. et al. Prevalence and incidence of androgen deficiency in middle-aged and older men: Estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004; 89: 5920-5926
- 7 Wu FC, Tajar A, Beynon JM. et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med 2010; 363: 123-135
- 8 Kapoor D, Malkin CJ, Channer KS. et al. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005; 63: 239-250
- 9 Kapoor D, Aldred H, Clark S. et al. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007; 30: 911-917
- 10 Kapoor D, Goodwin E, Channer KS. et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906
- 11 Malkin CJ, Pugh PJ, West JN. et al. Testosterone therapy in men with moderate severity heart failure: A double-blind randomized placebo controlled trial. Eur Heart J 2006; 27: 57-64
- 12 Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab 2008; 93: 68-75
- 13 Hackett G, Heald AH, Sinclair A. et al. Serum testosterone, testosterone replacement therapy and all-cause mortality in men with type 2 diabetes: retrospective consideration of the impact of PDE5 inhibitors and statins. Int J Clin Pract 2016; 70: 244-253
- 14 Carnevale Schianca et al. Exp Clin Endocrinol Diabetes 2017; 125: 171-175
- 15 Atlantis E, Fahey P, Martin S. et al. Predictive value of serum testosterone for type 2 diabetes risk assessment in men. BMC Endocr Disord 2016; 27: 16
- 16 Kloner et al. Testosterone and Cardiovascular Disease. J Am Coll Cardiol 2016; 67: 545-557
- 17 Townsend P, Phillimore P, Beattie A. Health and deprivation: Inequality and the North. Routledge; 1988
- 18 Mazer NA. A novel spreadsheet method for calculating the free serum concentrations of testosterone, dihydrotestosterone, estradiol, estrone and cortisol: With illustrative examples from male and female population. Steroids 2009; 74: 512-519
- 19 Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999; 84: 3666-3672
- 20 Citron JT, Ettinger B, Rubinoff H. et al. Prevalence of hypothalamic-pituitary imaging abnormalities in impotent men with secondary hypogonadism. The Journal of urology. 1996; 155: 529-533
- 21 Preethi M, Rao PM, Kelly DM. et al. Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nature Reviews Endocrinology 2013; 9: 479-493
- 22 Wang C, Nieschlag E, Swerdloff R. et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008; 159: 507-514
- 23 Bhasin S, Cunningham GR, Hayes FJ. et al. Testosterone therapy in men with androgen deficiency syndromes: An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2010; 95: 2536-2559
- 24 Martinez et al. Testosterone treatment and risk of venous thromboembolism BMJ. BMJ 2016; 355: i5968
- 25 Khaw KT, Dowsett M, Folkerd E. et al. Endogenous testosterone and mortality due to all causes, cardiovascular disease, and cancer in men: European prospective investigation into cancer in Norfolk (EPIC-Norfolk) Prospective Population Study. Circulation 2007; 116: 2694-2701
- 26 Wang C, Jackson G, Jones TH. et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care 2011; 34: 1669-1675
- 27 Anderson SG, Heald A, Younger N. et al. Screening for hypogonadism in diabetes 2008/9: results from the Cheshire Primary Care cohort. Primary care diabetes 2012; 6: 143-188
- 28 Oh JY, Barrett-Connor E, Wedick NM. et al. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002; 25: 55-60
- 29 Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male 2003; 6: 1-7
- 30 Heufelder AE, Saad F, Bunck MC. et al. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. J Androl 2009; 30: 726-733
- 31 Kalinchenko SY, Tishova YA, Mskhalaya GJ. et al. Supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010; 73: 602-612
- 32 Jones TH, Arver S, Behre HM. et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes care 2011; 34: 828-837